SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-190489
Filing Date
2023-07-20
Accepted
2023-07-20 16:06:29
Documents
16
Period of Report
2023-07-18
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d467661d8k.htm   iXBRL 8-K 29860
2 EX-1.1 d467661dex11.htm EX-1.1 204248
3 EX-5.1 d467661dex51.htm EX-5.1 6478
4 EX-99.1 d467661dex991.htm EX-99.1 4996
8 GRAPHIC g467661dsp49.jpg GRAPHIC 3351
  Complete submission text file 0001193125-23-190489.txt   432818

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA abos-20230718.xsd EX-101.SCH 2851
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE abos-20230718_lab.xml EX-101.LAB 17979
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE abos-20230718_pre.xml EX-101.PRE 11259
10 EXTRACTED XBRL INSTANCE DOCUMENT d467661d8k_htm.xml XML 3341
Mailing Address 427 PARK ST. CHARLOTTESVILLE VA 22902
Business Address 427 PARK ST. CHARLOTTESVILLE VA 22902 925-368-8508
Acumen Pharmaceuticals, Inc. (Filer) CIK: 0001576885 (see all company filings)

IRS No.: 364108129 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40551 | Film No.: 231099798
SIC: 2836 Biological Products, (No Diagnostic Substances)